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Neurokinin B (NKB) is a hypothalamic neuropeptide binding preferentially to the neurokinin 3 receptor.
Expression of the gene encoding NKB is elevated in postmenopausal women. Furthermore, rodent studies
suggest that NKB signalling may mediate menopausal hot flushes. However, the effects of NKB
administration on hot flushes have not been investigated in humans. To address this, we performed a
randomised, double-blinded, placebo-controlled, 2-way cross-over study. Ten healthy women were
admitted to a temperature and humidity-controlled research unit. Participants received 30 minute
intravenous infusions of NKB and vehicle in random order. Symptoms, heart rate, blood pressure, sweating
and skin temperature were compared between NKB and vehicle in a double-blinded manner. Eight of ten
participants experienced flushing during NKB infusion with none experiencing flushing during vehicle
infusion (P 5 0.0007). Significant elevations in heart rate (P 5 0.0106 vs. pre-symptoms), and skin
temperature measured using skin probe (P5 0.0258 vs. pre-symptoms) and thermal imaging (P5 0.0491
vs. pre-symptoms) characteristic of menopausal flushing were observed during hot flush episodes. Our
findings provide evidence that NKB administration can cause hot flushes in women. Further studies are
required to determine if pharmacological blockade of NKB signalling could inhibit hot flushes during the
menopause and during treatment for sex-steroid dependent cancers.
H
ot flushes (or flashes) are intermittent episodes of sweating and heat sensation associated with decreasing
circulating sex steroid levels. Hot flushes are experienced by 70–80% of women during the menopausal
transition and postmenopause, and can have a significant negative impact on quality of life1–3. Hot flushes
are also experienced bymany patients undergoing sex steroid deprivation therapy for breast and prostate cancer4.
Hormone replacement therapy (HRT) is the most effective and commonly used pharmacological treatment for
menopausal hot flushes. However, current guidelines recommend a limited duration of HRT therapy due to the
associated risks (e.g. breast cancer, coronary artery disease, stroke, and thromboembolism)5. Furthermore HRT is
contra-indicated in many patients (e.g. history of thromboembolic disease, breast/endometrial cancer, liver
disease), andmay be unsuitable for patients with hormone-dependent cancers undergoing sex steroid deprivation
therapy5. Other therapies such as selective serotonin reuptake inhibitors (SSRIs), gabapentin, and clonidine can
be used to treat hot flushes. However these treatments are less effective than HRT and have a number of
commonly associated adverse effects such as sedation, nausea and orthostatic hypotension2,6,7. There is therefore
a major need to identify therapeutic targets to treat hot flushes more effectively.
Menopausal flushes are triggered by a fall in circulating sex steroid levels. Furthermore, thermoregulatory
centres in the hypothalamus are thought to play a crucial role in mediating the hot flush response. However,
the central mechanisms through which sex steroid deficiency triggers flushing remain unclear. Learning more
about the mechanisms governing hot flushes may allow us to identify novel therapeutic targets to better treat
patients affected by these symptoms. It has recently emerged that the hypothalamic hormone, neurokinin B (NKB)
may play an important role in linking oestrogen deficiency to hot flushes. NKB is a decapeptide and a member of
the tachykinin family of peptides8. In humans, NKB is encoded by the TAC3 gene and binds preferentially to the
neurokinin 3 receptor (NK3R, encoded by the TAC3R gene)9. Hypothalamic NKB expression is elevated during
menopause, and restored to normal levels with oestrogen replacement in monkeys10–12. Furthermore, rodent
studies suggest that the flushing response to oestrogen deficiency may be dependent on endogenous hypothalamic
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NKB signalling13. These animal data combined suggest that NKB
signalling may be crucial in the hot flush aetiology.
The question of whether exogenous NKB can induce hot flushes in
humans has not yet been investigated. We performed a randomised,
double-blinded, placebo-controlled, two-way cross-over study to
determine the effects of NKB administration on hot flushes in
women.
Methods
All experimental protocols were approved by the National Research Ethics Service
(NRES) Committee London –West London (registration number 10/H0707/68) and
were performed in accordance with the Declaration of Helsinki. Written informed
consent was obtained from all participants. See Supplementary Methods online for
participant characteristics, peptide characteristics, and protocol for blood collection
and analysis.
Study 1: Symptom assessment study during intravenous (iv) infusion of NKB to
healthy women. Participants were admitted in the morning to our Clinical
Investigation Unit between days 3 and 10 of their menstrual cycle, and asked to lay
supine for the 180 minute study duration (Figure 1). For participant characteristics
see Supplementary Table S1 online. A cannula was inserted into a large forearm vein
and NKB (5.12 nmol/kg/min) was administered by intravenous (iv) infusion for 30
minutes commencing at t 5 90 minutes. We selected this dose of NKB as it was the
maximal dose that was well-tolerated dose in our previous studies14. NKB was
dissolved in saline containing gelofusin (5% vol/vol) (B.BraunMedical, Sheffield, UK)
tominimize peptide adsorption15. Participants (but not investigators) were blinded as
to the identity of the infusion (NKB or vehicle, however all participants received
NKB). Participants were informed before the study that they may experience body
sensations or symptoms and they were asked to report these in real time during the
study. Participants were not specifically informed that theymay experience ‘hot flush’
symptoms so as tominimise reporting bias.We employed subjective reporting of ‘hot
flush’ symptoms as it is currently the most accurate method for detection and
assessment of hot flushes (see review by Sievert) and is therefore the preferredmethod
for clinical studies in the field16–19.
Study 2: Detailed physiological assessment study during iv infusion of NKB and
vehicle to healthy women. Having observed in Study 1 that participants reported
flushing during NKB infusion we carried out a double-blinded placebo-controlled
study. This was performed in a climate-controlled Clinical Research Unit with
ambient temperature 24uC and humidity 50% as established in previous studies to be
a suitable environment to investigate menopausal flushing20–23. Participants were
admitted on a morning between days 3 and 10 of their menstrual cycle, and asked to
lay supine for the 270 minute study duration (Supplementary Figure S1 online). For
participant characteristics see Supplementary Table S2 online. A cannula was inserted
into a large forearm vein in both arms: one for collection of blood, and the second for
vehicle (gelofusin) or NKB infusion. 30minute iv infusion of either NKB (5.12 nmol/
kg/h) or vehicle (equivalent volume) were commenced at t 5 60 minutes and t 5
180minutes (90 minute washout period between infusions), by an investigator
blinded to the identity of each infusion. Each participant received one NKB infusion
and one vehicle infusion, randomised and prepared by an independent investigator.
Participants were informed that they could receive any of the following: NKB
followed by vehicle; vehicle followed by NKB; NKB twice; vehicle twice. This strategy
ensured integrity of blinding, since any symptoms experienced during the first
infusion would not allow participants to automatically deduce the identity of the
second infusion.
In order to prevent confounding factors which may affect flushing, participants
were asked to refrain from hot drinks, caffeine, alcohol and spicy foods for 12 hours
preceding the study start and for the duration of the study. All participants wore light
cotton standard hospital gowns. All studies commenced between 9.30–10.30am. Two
experienced physicians were in attendance at all times. As in Study 1, subjective hot
flush symptoms were self-reported by the participants. In addition heart rate, blood
pressure, sweating and skin temperature monitoring were performed as detailed
below:
Heart rate (HR) and mean arterial blood pressure (MAP). HR was recorded
minutely for 20 minutes pre-infusion until 20 minutes post-infusion. MAP was
recorded at 5 minute intervals (to minimize discomfort) for 20 minutes pre-infusion
until 20 minutes post-infusion. At other times HR and MAP were recorded at 10
minute intervals (Supplementary Figure S1 online). MAP (in mmHg) was calculated
using the following standard formula: MAP 5 ((2 x diastolic BP) 1 systolic BP)/3.
Skin temperature. Skin temperature was recorded each minute for 20 minutes pre-
infusion until 20minutes post-infusion and at 10minute intervals at other times. Skin
temperature wasmeasured by skin temperature probe attached to the neck (Mindray,
Huntingdon, UK) and by thermal imaging camera (T440Bx, Flir, Wilsonville, USA).
Thermal imaging temperature values were determined by in-built software which
recorded the highest temperature point in a box constructed to contain the shoulders
and head of the participant.
Skin conductance. Increased skin conductance is an objective marker of sweating
which occurs in menopausal flushing. Sternal skin conductance (SSC) was measured
using a previously described Bahr hot flush monitor that measured SSC in
microsiemens (mS) every 10 seconds by passing an electric current across two
electrodes attached to the sternal region of the chest (Simplex Scientific, Wisconsin,
USA)19,24,25.
Symptoms. On arrival on the study day participants were asked to report their
general stress level that day on a scale 1–3 (1-no stress, 2-mild stress, 3-high stress)
(Table 1). They were also asked to verbally report any symptoms of any nature that
they experienced including their frequency and severity to the study investigators in
real-time during the study. As in Study 1, participants were informed before the study
that they may experience body sensations or symptoms but were not specifically
informed that they may experience ‘hot flush’ symptoms so as to minimise reporting
bias. Symptom data was collected by an independent investigator blinded to the
identities of infusions administered during the study.
Reproductive hormones. Blood was collected for luteinizing hormone (LH), follicle
stimulating hormone (FSH) and estradiol (E2) at intervals of 10 minutes throughout
the study (see Supplementary Methods online).
Data analysis. The occurrence of flushing was analysed by two-tailed Fisher’s exact
test. Physiological data passed Kolmogorov-Smirnov testing for normality. Paired
Figure 1 | Participant-reported hot flush symptoms during 30 minute intravenous infusion of neurokinin B (Study 1). Five healthy women were
monitored for 180minutes in a Clinical ResearchUnit. They were administered an intravenous infusion of neurokinin B (NKB, 5.12 nmol/kg/h) between
90–120 minutes. Red ovals represent timings and duration of participant-reported hot flush symptoms. Hot flush symptoms were reported by four
out of five participants.
www.nature.com/scientificreports
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means were compared using two-tailed paired t-tests and change in means were
compared using two-tailed one-sample t-tests (equivalent results). P , 0.05 was
considered statistically significant. Data are presented as mean 6 standard error of
mean (SEM).
Results
Study 1: Effects of 30 minute intravenous infusion of NKB on
flushing symptoms in healthy women. We performed a pilot
study investigating whether a 30 minute infusion of 5.12 nmol/kg/
h NKB could induce flushing symptoms in healthy women during
the follicular phase of menstrual cycle.
Flushing symptoms (e.g. warmth, heat, sweating) were only
reported during NKB infusion with no flushing symptoms reported
during the 90 minutes pre-NKB infusion or the 60 minutes post-
NKB infusion. Flushing was reported by four out of the five partici-
pants during NKB infusion (Figure 1). Three of the four participants
experiencing flushing reported a single flushing episode during NKB
infusion, and one participant experienced three flushing episodes
during NKB infusion.
Study 2: Effects of 30 minute intravenous infusion of NKB versus
vehicle on symptoms and objective clinical markers of flushing in
healthy women. To determine the effects of NKB on flushing in
further detail, ten healthy women were administered a 30 minute
intravenous infusion of vehicle and a 30minute intravenous infusion
of 5.12 nmol/kg/h NKB during the same study visit, in random order
(Supplementary Figure S1 online).
Flushing episodes during vehicle and NKB.No flushing symptoms
were recorded during infusion of vehicle in healthy women
(Figure 2). Flushing symptoms were only reported during NKB
infusion and ranged from mild to strong (mean severity 2/3 5
strong heat sensation, See Table 1). During NKB infusion eight out
of ten participants experienced flushing (P 5 0.007 vs. vehicle) (of
these participants, five experienced a single flushing episode, one
experienced two flushing episodes, and two participants each
experienced three flushing episodes, Figure 2 and Table 1). All first
flushing episodes commenced between 1–12 minutes after NKB
infusion initiation (Figure 2). As high stress levels are known to
influence hot flush reporting in menopausal women, we collected
pre-study stress scores2,3. No participant reported high pre-study
stress levels (See Table 1).
Concordant increases in sternal skin conductance (suggestive of
sweating) were evident in six of the eight participants at the time of
flushing during their NKB infusion (concordance was defined as an
objectively-measured sternal skin conductance response corrobo-
rated by a subjective self-report of a flush19).
Changes in heart rate, temperature and blood pressure during
flushing episodes. We investigated specifically whether HR,
temperature (measured using skin temperature probe and thermal
imaging camera), or MAP were altered specifically during flushing
symptoms occurring during NKB infusion. Mean HR increased
significantly during flushing symptoms when compared with the
pre-symptom period (mean HR in bpm: 70.3 6 2.1, pre-
symptoms; 76.2 6 1.6, symptoms, P 5 0.0106 vs. pre-symptoms)
(Figure 3a–b). Mean skin temperature increased significantly during
flushing symptoms when compared with the pre-symptom period,
whether measured using skin probe (mean temperature in Celsius:
34.66 0.2, pre-symptoms; 34.760 .3, symptoms, P5 0.0258 vs. pre-
symptoms) or using thermal imaging camera (mean temperature in
Celsius: 36.7 6 0.1, pre-symptoms; 36.8 6 0.1, symptoms, P 5
0.0491 vs. pre-symptoms) (Figure 3c–f). No significant change in
MAP was observed flushing symptoms when compared with the
pre-symptom period (mean MAP in mmHg: 83.2 6 8.6, pre-
symptoms; 82.5 6 2.2, symptoms, P 5 0.546 vs. pre-symptoms)
(Figure 3g–h).
Overall changes in heart rate, temperature and blood pressure
during entire vehicle and NKB infusions. No overall changes in
HR, skin temperature (measured using skin probe or thermal
imaging camera), or mean arterial blood pressure (MAP) were
observed between vehicle and NKB infusions when comparing the
measurements over the entire duration of the infusion
(Supplementary Figure S2 online); hence physiological changes
were specific to hot flush episodes and not present for the duration
of NKB infusion.
Table 1 | Participant-reported symptoms during double-blinded administration of vehicle and neurokinin B (Study 2). Ten healthy women
were administered 30 min intravenous infusions of vehicle and neurokinin B (NKB, 5.12 nmol/kg/h) with a 90 min interval between
infusions. Vehicle was administered first in participants 1,2,5,7 and 9, and NKB was administered first in participants 3,4,6,8 and 10.
Participants were asked to verbally report any symptoms including their frequency and severity (0 no symptom, 1 mild heat sensation, 2
strong heat sensation and able to continue with general activity, 3 strong heat sensation unable to continue with current activity) to the study
investigators in real-time during the study. Pre-study stress scores (1 low, 2 medium, 3 high) were recorded on arrival for the study
Participant Number
Pre-Study Stress
Score (1–3)
Participant-reported symptoms
Maximum symptoms
severity (0–3)1st infusion 2nd infusion
VEHICLE NKB
1 1 None Hot forehead, Hot ears, Headache, Warm 2
2 1 None Hot face, Facial flushing, Headache, Warm 3
5 2 None Hot face, ‘Hot air blowing on face’,
Headache, Warm
2
7 1 None None 0
9 1 None Flushing, Clammy, ‘Face burning’, Warm
face/arms
2
NKB VEHICLE
3 2 Cheeks flushing, Warm None 2
4 1 Warm face, Cold following warm None 2
8 1 None None 0
6 1 Hot head, Sweating, Head tingling,
Clammy, Warm
None 1
10 1 Feels hot, Face sweating, Warm None 1
www.nature.com/scientificreports
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Changes in serum reproductive hormones during vehicle and
NKB. No significant changes in serum LH, FSH or estradiol were
observed during the entire 30 minute NKB infusion period when
compared with vehicle infusion period (Figure 4).
Discussion
Millions of post-menopausal women and patients undergoing cancer
treatments suffer hot flushes worldwide26. An improved understand-
ing of the central mechanisms responsible for hot flushes may lead to
Figure 2 | Participant-reported hot flush symptoms during double-blinded administration of vehicle and neurokinin B (Study 2). The order of
infusions was randomised by an independent investigator. (a) Participants 1,2,5,7 and 9 received vehicle infusion first and NKB infusion second. (b)
Participants 3,4,6,8 and 10 receivedNKB infusion first then vehicle infusion second. Red ovals represent timings and duration of participant-reported hot
flush symptoms. Hot flush symptoms were reported by eight out of ten participants. There were a total of thirteen separate flushing episodes.
Figure 3 | Physiological changes associated with hot flush episodes in healthy women. Mean heart rate (a), skin temperature by skin probe (c), skin
temperature by thermal imaging (e) andmean arterial pressure (MAP) (g), during 5minute period pre-symptom onset (Pre-symp) and during symptom
period (Symp) using the minutely recordings. Parts b, d, f and h represent change in respective physiological parameter when compared with
pre-symptom level. AsMAPwas recorded every 5minutes (rather thanminutely so as to avoid discomfort), theMAPmeasurement immediately prior to
symptoms was compared to that at symptom onset or closest after symptom onset. Data presented as mean 6 SEM. *P , 0.05.
www.nature.com/scientificreports
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novel therapies for affected patients, particularly those in whom
HRT is contraindicated. Recent data have implicated NKB signalling
as an important mediator in menopausal flushing. Hypothalamic
NKB neurones exhibit marked hypertrophy and NKB expression
increases following the human menopause27. Moreover, hypothala-
mic NKB neurones also undergo hypertrophy and NKB expression
increases following ovariectomy in monkeys, while estradiol replace-
ment restores NKB neurones to a size comparable to ovary-intact
monkeys10,12. Furthermore, ablating NKB receptor-expressing neu-
rones (NK3R) within the hypothalamic arcuate nucleus using
NK3R-saporin, blocks the typical changes in tail skin and core body
temperature in observed in rats following ovariectomy13. The effects
of NKB on flushing may be mediated within the hypothalamic med-
ian preoptic nucleus (MnPO). The MnPO expresses the neurokinin
3 receptor (NK3R), and receives information from warm-sensitive,
cutaneous thermoreceptors and projects to CNS centres to modulate
heat dissipation effectors28,29. C-fos expression (a marker of neuronal
activation) in the MnPO increases in ovariectomised rats when
compared with ovariectomised and estrogen-replaced rats30.
Furthermore, micro-infusion of the NK3R agonist, senktide, into
the MnPO reduces core temperature30.
Collectively, the current and previous studies suggest that an
increase in NKB signalling may trigger hot flushes during oestrogen
sex steroid deficiency. Our data suggests that intravenous infusion of
NKB induces hot flushes in healthy women. This is consistent with
previous rodent data implicating the NKB signalling pathway as a
novel therapeutic target for menopausal hot flushes. A number of
NK3R antagonists have already been evaluated in humans for the
potential treatment of schizophrenia31. It would therefore be inter-
esting in future studies to test whether NK3R antagonists could
inhibit endogenous hot flushes in patients with sex steroid deficiency.
We took a number of precautions during the current study to
optimise data quality and reduce bias. We used subjective reports
of flushing as the primary endpoint of this study, since it is the gold-
standard diagnosticmeasure (and the definition, itself) of hot flushes.
We alsomeasured objective clinical indices such as skin temperature,
HR and skin conductance which are commonly altered during nat-
ural menopausal flushing episodes32–37. All study visits were sched-
uled during days 3 to 10 of the menstrual cycle (follicular phase)
when core body temperature is most stable. In addition participants
received standardised instructions from a study investigator prior to
each visit, and were asked to verbally report frequency and severity of
any body sensations or symptoms in real time during the study.
Furthermore participants were not specifically informed that they
may experience ‘hot flush’ symptoms to avoid reporting bias. During
Study 2, participants received one infusion of vehicle and one infu-
sion of NKB, in random order; therefore in order to prevent the
identity of the second infusion being deduced from symptoms
experienced during the first infusion, all participants and bedside
investigators were intentionally told that either or both infusions
could contain NKB (when in fact, only one of the two infusions
would contain NKB). Finally, Study 2 allowed us to compare the
effects of vehicle and NKB on flushing during the same study visit.
Our data showed that the primary endpoint, i.e. hot flush symptom,
was only observed during NKB infusion in healthy premenopausal
women.
Menopausal flushing is known to be associated with increases in
heart rate and skin temperature2. During menopausal hot flushes,
HR has been reported to increase by approximately 5–15 beats per
minute without coincident change in blood pressure35, and increases
in skin temperature of 0.2–1.0uChave also been reported32,38. Indeed,
during the current study, both HR and skin temperature increased
significantly and by similar magnitudes to natural menopausal
flushes. In addition, it is important to note that overall mean levels
of HR, MAP and skin temperature were similar between entireNKB
and vehicle infusions in healthywomen, which suggests thatNKB per
se does not affect these parameters (i.e. significant changes were
specific and confined to hot flush episodes rather than over the entire
infusion duration). Our results therefore suggest that NKB elicits hot
flushing episodes in women, which are accompanied by objective
Figure 4 | Reproductive hormone changes during neurokinin B and vehicle infusion. Serum luteinizing hormone (LH) (a), serum follicle stimulating
hormone (FSH) (c) and serum estradiol (e) levels during neurokinin B (NKB) and vehicle infusion. Parts b, d and f represent change in respective
parameter when compared with vehicle. Data presented as mean 6 SEM.
www.nature.com/scientificreports
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physiological effects similar to those observed inmenopausal flushes.
Sternal skin conductance, a surrogate marker of sweating also
showed increases in 6/8 women in study 2, at the time of flushing
episodes reported during NKB administration.
NKB is co-expressed within the arcuate nucleus with two other
neuropeptides (kisspeptin and dynorphin) in kisspeptin-dynorphin-
neurokinin B (KNDy) neurones, which regulate the secretion of
gonadotrophin releasing hormone39. Inactivating mutations in
TAC3 or TAC3R cause pubertal failure in humans40,41. It was there-
fore important to measure any effects of NKB on reproductive hor-
mone release. In this study we found at the dose tested, NKB had no
significant effects on reproductive hormone release (consistent with
our previous study investigating the effects of intravenous NKB
administration on reproductive hormone secretion in healthy men
and women14).
It is interesting to consider whether the effects of NKB we have
observed in this study are due to NKB action at central or peripheral
NK3Rs. The various physiological parameters were not raised
throughout the NKB infusion period, only during the acute inter-
mittent hot flushes which favours a central site of NKB action. This is
in keeping with data from animals which shows that microinfusion
of NK3 agonist (senktide) centrally into the rat MnPO modulates
body temperature30. Furthermore, ablation of NK3-expressing neu-
rones inhibits cutaneous vasodilation in rats as measured by tail-skin
temperature13. However, NKB administration was not associated
with gonadotropin secretion and hence this may suggest NKB
actions at peripheral NK3Rs also contribute to the effects observed
in our study. Whilst TAC3 and TAC3R genes are predominantly
expressed centrally there is also expression in several peripheral tis-
sues including the reproductive, gastrointestinal and respiratory
tracts with putative contributory roles in epithelial cell function,
gastric motility, and airway physiology amongst others42. Hence
although the effects of NKB observed in the current study are con-
sistent with a central site of NKB action, we cannot exclude the
possibility that NKB acting at peripheral NK3Rs could be contrib-
uting to the effects we have observed.
In summary, our data shows that intravenous infusion of NKB
acutely induces hot flushes in premenopausal healthy women.
Further studies are required to determine if pharmacological block-
ade of NKB signalling could inhibit hot flushes associated with the
menopause and treatment for sex-steroid dependent cancers.
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